Springfield Chronicle

Cholangiocarcinoma (CCA) Market Insights, Epidemiology and Market Forecast 2030

 Breaking News
  • No posts were found

Cholangiocarcinoma (CCA) Market Insights, Epidemiology and Market Forecast 2030

April 03
21:25 2020
Cholangiocarcinoma (CCA) Market Insights, Epidemiology and Market Forecast 2030

DelveInsight Business Research LLP
DelveInsight’s “Cholangiocarcinoma (CCA) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Cholangiocarcinoma (CCA), historical and forecasted epidemiology as well as the Cholangiocarcinoma (CCA) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight launched a new report on Cholangiocarcinoma (CCA) – Market Insights, Epidemiology, and Market Forecast-2030.

DelveInsight’s “Cholangiocarcinoma (CCA) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Cholangiocarcinoma (CCA), historical and forecasted epidemiology as well as the Cholangiocarcinoma (CCA) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Key fact from the report:

“Among the EU5 countries, Germany had the highest incident population of Cholangiocarcinoma (CCA) with 4,471 cases, followed by Italy and the United Kingdom. On the other hand, Spain had the lowest incident population.”

Request for sample pages: https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-market

“Males are more prone to Cholangiocarcinoma than females in all countries. Cholangiocarcinoma overall incidence in both the genders is subjected to increase in the coming years”

Currently, Cholangiocarcinoma or Bile Duct Cancer market size for early-stage majorly includes surgery with adjuvant chemotherapy and chemoradiation therapy. For the advanced and metastatic stage, systemic chemotherapy is the only option. There is no established second-line systemic therapy the following progression after first-line treatment although chemotherapeutic agents either in monotherapy or in combination are used.

Key pharma players:
1. Agios Pharmaceuticals
2. Bayer
3. Basilea Pharmaceutica
4. Delcath Systems
5. Hoffmann-La Roche
6. Incyte Corporation
and many others.

Drugs involved are:
1. AG-120
2. Pemigatinib
3. Infigratinib
4. Regorafenib
5. LOXO-101
6. Entrectinib
and many others

Request a free sample report: https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-market

Table of contents:
1. Key Insights
2. Executive Summary of Cholangiocarcinoma (CCA)
3. Competitive Intelligence Analysis for Cholangiocarcinoma (CCA)
4. Cholangiocarcinoma (CCA): Market Overview at a Glance
5. Cholangiocarcinoma (CCA): Disease Background and Overview
6. Patient Journey
7. Cholangiocarcinoma (CCA) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Cholangiocarcinoma (CCA) Treatment
11. Marketed Products
12. Emerging Therapies
13. Cholangiocarcinoma (CCA): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Cholangiocarcinoma (CCA)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

About DelveInsight:
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/